<DOC>
	<DOCNO>NCT00276341</DOCNO>
	<brief_summary>The purpose study determine whether use EGb 761 patient Relapsing-Remitting Multiple Sclerosis effective improve cognition , compare placebo .</brief_summary>
	<brief_title>Study Effectiveness EGb 761® Vs Placebo Used Cognitive Impairment Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Patient Multiple Sclerosis RelapsingRemitting form Patient cognitive impairment ( spontaneous complaint either patient family ) Patient treat interferon maintain dosage previous 6 month Patient without major disability ( Kurtzke Extended Disability Status Scale ≤6 ) Clinical Multiple Sclerosis relapse within 3 month prior participation Major psychiatric disease accord Diagnostic Statistical Manual Mental Disorders , 4th Ed . Other concomitant disorder possibly jeopardize cognitive status evaluation follow patient ( severe impairment visual motor function may prevent participation neuropsychological testing )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>cognitive impairment</keyword>
</DOC>